BIOMAT Database Logo BIOMAT Database Logo

Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. 2022

Takao Morinaga, and Takashi Inozume, and Masahito Kawazu, and Youki Ueda, and Nicolas Sax, and Kazuo Yamashita, and Shusuke Kawashima, and Joji Nagasaki, and Toshihide Ueno, and Jason Lin, and Yuuki Ohara, and Takeshi Kuwata, and Hiroki Yukami, and Akihito Kawazoe, and Kohei Shitara, and Akiko Honobe-Tabuchi, and Takehiro Ohnuma, and Tatsuyoshi Kawamura, and Yoshiyasu Umeda, and Yu Kawahara, and Yasuhiro Nakamura, and Yukiko Kiniwa, and Ayako Morita, and Eiki Ichihara, and Katsuyuki Kiura, and Tomohiro Enokida, and Makoto Tahara, and Yoshinori Hasegawa, and Hiroyuki Mano, and Yutaka Suzuki, and Hiroyoshi Nishikawa, and Yosuke Togashi
Chiba Cancer Center, Research Institute, Chiba, Japan.

Some patients experience mixed response to immunotherapy, whose biological mechanisms and clinical impact have been obscure. We obtained two tumor samples from lymph node (LN) metastatic lesions in a same patient. Whole exome sequencing for the both tumors and single-cell sequencing for the both tumor-infiltrating lymphocytes (TIL) demonstrated a significant difference in tumor clonality and TILs' characteristics, especially exhausted T-cell clonotypes, although a close relationship between the tumor cell and T-cell clones were observed as a response of an overlapped exhausted T-cell clone to an overlapped neoantigen. To mimic the clinical setting, we generated a mouse model of several clones from a same tumor cell line. Similarly, differential tumor clones harbored distinct TILs, and one responded to programmed cell death protein 1 (PD-1) blockade but the other did not in this model. We further conducted cohort study (n = 503) treated with PD-1 blockade monotherapies to investigate the outcome of mixed response. Patients with mixed responses to PD-1 blockade had a poor prognosis in our cohort. Particularly, there were significant differences in both tumor and T-cell clones between the primary and LN lesions in a patient who experienced tumor response to anti-PD-1 mAb followed by disease progression in only LN metastasis. Our results underscore that intertumoral heterogeneity alters characteristics of TILs even in the same patient, leading to mixed response to immunotherapy and significant difference in the outcome. Several patients experience mixed responses to immunotherapies, but the biological mechanisms and clinical significance remain unclear. Our results from clinical and mouse studies underscore that intertumoral heterogeneity alters characteristics of TILs even in the same patient, leading to mixed response to immunotherapy and significant difference in the outcome.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D016246 Lymphocytes, Tumor-Infiltrating Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer. Tumor Infiltrating Lymphocyte,Tumor-Derived Activated Cell,Tumor-Derived Activated Cells,Tumor-Infiltrating Lymphocyte,Tumor-Infiltrating Lymphocytes,Activated Cell, Tumor-Derived,Activated Cells, Tumor-Derived,Infiltrating Lymphocyte, Tumor,Infiltrating Lymphocytes, Tumor,Lymphocyte, Tumor Infiltrating,Lymphocyte, Tumor-Infiltrating,Lymphocytes, Tumor Infiltrating,Tumor Derived Activated Cell,Tumor Derived Activated Cells,Tumor Infiltrating Lymphocytes
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Takao Morinaga, and Takashi Inozume, and Masahito Kawazu, and Youki Ueda, and Nicolas Sax, and Kazuo Yamashita, and Shusuke Kawashima, and Joji Nagasaki, and Toshihide Ueno, and Jason Lin, and Yuuki Ohara, and Takeshi Kuwata, and Hiroki Yukami, and Akihito Kawazoe, and Kohei Shitara, and Akiko Honobe-Tabuchi, and Takehiro Ohnuma, and Tatsuyoshi Kawamura, and Yoshiyasu Umeda, and Yu Kawahara, and Yasuhiro Nakamura, and Yukiko Kiniwa, and Ayako Morita, and Eiki Ichihara, and Katsuyuki Kiura, and Tomohiro Enokida, and Makoto Tahara, and Yoshinori Hasegawa, and Hiroyuki Mano, and Yutaka Suzuki, and Hiroyoshi Nishikawa, and Yosuke Togashi
Hypoxia-driven intratumor heterogeneity and immune evasion.
November 2020, Cancer letters,
Takao Morinaga, and Takashi Inozume, and Masahito Kawazu, and Youki Ueda, and Nicolas Sax, and Kazuo Yamashita, and Shusuke Kawashima, and Joji Nagasaki, and Toshihide Ueno, and Jason Lin, and Yuuki Ohara, and Takeshi Kuwata, and Hiroki Yukami, and Akihito Kawazoe, and Kohei Shitara, and Akiko Honobe-Tabuchi, and Takehiro Ohnuma, and Tatsuyoshi Kawamura, and Yoshiyasu Umeda, and Yu Kawahara, and Yasuhiro Nakamura, and Yukiko Kiniwa, and Ayako Morita, and Eiki Ichihara, and Katsuyuki Kiura, and Tomohiro Enokida, and Makoto Tahara, and Yoshinori Hasegawa, and Hiroyuki Mano, and Yutaka Suzuki, and Hiroyoshi Nishikawa, and Yosuke Togashi
Heterogeneity of immune infiltration and immunotherapy in colorectal cancer.
January 2024, Gastroenterology report,
Takao Morinaga, and Takashi Inozume, and Masahito Kawazu, and Youki Ueda, and Nicolas Sax, and Kazuo Yamashita, and Shusuke Kawashima, and Joji Nagasaki, and Toshihide Ueno, and Jason Lin, and Yuuki Ohara, and Takeshi Kuwata, and Hiroki Yukami, and Akihito Kawazoe, and Kohei Shitara, and Akiko Honobe-Tabuchi, and Takehiro Ohnuma, and Tatsuyoshi Kawamura, and Yoshiyasu Umeda, and Yu Kawahara, and Yasuhiro Nakamura, and Yukiko Kiniwa, and Ayako Morita, and Eiki Ichihara, and Katsuyuki Kiura, and Tomohiro Enokida, and Makoto Tahara, and Yoshinori Hasegawa, and Hiroyuki Mano, and Yutaka Suzuki, and Hiroyoshi Nishikawa, and Yosuke Togashi
Differential Infiltration of Immune Cells Driven by Tumor Heterogeneity Reveals Two Immune Subtypes in Lung Adenocarcinoma.
January 2022, Frontiers in genetics,
Takao Morinaga, and Takashi Inozume, and Masahito Kawazu, and Youki Ueda, and Nicolas Sax, and Kazuo Yamashita, and Shusuke Kawashima, and Joji Nagasaki, and Toshihide Ueno, and Jason Lin, and Yuuki Ohara, and Takeshi Kuwata, and Hiroki Yukami, and Akihito Kawazoe, and Kohei Shitara, and Akiko Honobe-Tabuchi, and Takehiro Ohnuma, and Tatsuyoshi Kawamura, and Yoshiyasu Umeda, and Yu Kawahara, and Yasuhiro Nakamura, and Yukiko Kiniwa, and Ayako Morita, and Eiki Ichihara, and Katsuyuki Kiura, and Tomohiro Enokida, and Makoto Tahara, and Yoshinori Hasegawa, and Hiroyuki Mano, and Yutaka Suzuki, and Hiroyoshi Nishikawa, and Yosuke Togashi
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.
July 2018, Immunity,
Takao Morinaga, and Takashi Inozume, and Masahito Kawazu, and Youki Ueda, and Nicolas Sax, and Kazuo Yamashita, and Shusuke Kawashima, and Joji Nagasaki, and Toshihide Ueno, and Jason Lin, and Yuuki Ohara, and Takeshi Kuwata, and Hiroki Yukami, and Akihito Kawazoe, and Kohei Shitara, and Akiko Honobe-Tabuchi, and Takehiro Ohnuma, and Tatsuyoshi Kawamura, and Yoshiyasu Umeda, and Yu Kawahara, and Yasuhiro Nakamura, and Yukiko Kiniwa, and Ayako Morita, and Eiki Ichihara, and Katsuyuki Kiura, and Tomohiro Enokida, and Makoto Tahara, and Yoshinori Hasegawa, and Hiroyuki Mano, and Yutaka Suzuki, and Hiroyoshi Nishikawa, and Yosuke Togashi
Diagnostic biomarker KIF23 is associated with immune infiltration and immunotherapy response in gastric cancer.
January 2023, Frontiers in oncology,
Takao Morinaga, and Takashi Inozume, and Masahito Kawazu, and Youki Ueda, and Nicolas Sax, and Kazuo Yamashita, and Shusuke Kawashima, and Joji Nagasaki, and Toshihide Ueno, and Jason Lin, and Yuuki Ohara, and Takeshi Kuwata, and Hiroki Yukami, and Akihito Kawazoe, and Kohei Shitara, and Akiko Honobe-Tabuchi, and Takehiro Ohnuma, and Tatsuyoshi Kawamura, and Yoshiyasu Umeda, and Yu Kawahara, and Yasuhiro Nakamura, and Yukiko Kiniwa, and Ayako Morita, and Eiki Ichihara, and Katsuyuki Kiura, and Tomohiro Enokida, and Makoto Tahara, and Yoshinori Hasegawa, and Hiroyuki Mano, and Yutaka Suzuki, and Hiroyoshi Nishikawa, and Yosuke Togashi
Lactate score predicts survival, immune cell infiltration and response to immunotherapy in breast cancer.
January 2022, Frontiers in genetics,
Takao Morinaga, and Takashi Inozume, and Masahito Kawazu, and Youki Ueda, and Nicolas Sax, and Kazuo Yamashita, and Shusuke Kawashima, and Joji Nagasaki, and Toshihide Ueno, and Jason Lin, and Yuuki Ohara, and Takeshi Kuwata, and Hiroki Yukami, and Akihito Kawazoe, and Kohei Shitara, and Akiko Honobe-Tabuchi, and Takehiro Ohnuma, and Tatsuyoshi Kawamura, and Yoshiyasu Umeda, and Yu Kawahara, and Yasuhiro Nakamura, and Yukiko Kiniwa, and Ayako Morita, and Eiki Ichihara, and Katsuyuki Kiura, and Tomohiro Enokida, and Makoto Tahara, and Yoshinori Hasegawa, and Hiroyuki Mano, and Yutaka Suzuki, and Hiroyoshi Nishikawa, and Yosuke Togashi
S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer.
January 2021, Frontiers in immunology,
Takao Morinaga, and Takashi Inozume, and Masahito Kawazu, and Youki Ueda, and Nicolas Sax, and Kazuo Yamashita, and Shusuke Kawashima, and Joji Nagasaki, and Toshihide Ueno, and Jason Lin, and Yuuki Ohara, and Takeshi Kuwata, and Hiroki Yukami, and Akihito Kawazoe, and Kohei Shitara, and Akiko Honobe-Tabuchi, and Takehiro Ohnuma, and Tatsuyoshi Kawamura, and Yoshiyasu Umeda, and Yu Kawahara, and Yasuhiro Nakamura, and Yukiko Kiniwa, and Ayako Morita, and Eiki Ichihara, and Katsuyuki Kiura, and Tomohiro Enokida, and Makoto Tahara, and Yoshinori Hasegawa, and Hiroyuki Mano, and Yutaka Suzuki, and Hiroyoshi Nishikawa, and Yosuke Togashi
KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer.
February 2022, Investigational new drugs,
Takao Morinaga, and Takashi Inozume, and Masahito Kawazu, and Youki Ueda, and Nicolas Sax, and Kazuo Yamashita, and Shusuke Kawashima, and Joji Nagasaki, and Toshihide Ueno, and Jason Lin, and Yuuki Ohara, and Takeshi Kuwata, and Hiroki Yukami, and Akihito Kawazoe, and Kohei Shitara, and Akiko Honobe-Tabuchi, and Takehiro Ohnuma, and Tatsuyoshi Kawamura, and Yoshiyasu Umeda, and Yu Kawahara, and Yasuhiro Nakamura, and Yukiko Kiniwa, and Ayako Morita, and Eiki Ichihara, and Katsuyuki Kiura, and Tomohiro Enokida, and Makoto Tahara, and Yoshinori Hasegawa, and Hiroyuki Mano, and Yutaka Suzuki, and Hiroyoshi Nishikawa, and Yosuke Togashi
ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer.
January 2024, Cell research,
Takao Morinaga, and Takashi Inozume, and Masahito Kawazu, and Youki Ueda, and Nicolas Sax, and Kazuo Yamashita, and Shusuke Kawashima, and Joji Nagasaki, and Toshihide Ueno, and Jason Lin, and Yuuki Ohara, and Takeshi Kuwata, and Hiroki Yukami, and Akihito Kawazoe, and Kohei Shitara, and Akiko Honobe-Tabuchi, and Takehiro Ohnuma, and Tatsuyoshi Kawamura, and Yoshiyasu Umeda, and Yu Kawahara, and Yasuhiro Nakamura, and Yukiko Kiniwa, and Ayako Morita, and Eiki Ichihara, and Katsuyuki Kiura, and Tomohiro Enokida, and Makoto Tahara, and Yoshinori Hasegawa, and Hiroyuki Mano, and Yutaka Suzuki, and Hiroyoshi Nishikawa, and Yosuke Togashi
Intratumor δ-catenin heterogeneity driven by genomic rearrangement dictates growth factor dependent prostate cancer progression.
May 2020, Oncogene,
Copied contents to your clipboard!